tirzepatide surpass cvot SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized Diabetes Distilled: SURPASS-CVOT – Tirzepatide

Call (509) 432-0182 to speak with Post Falls, Idaho Weight Loss doctor, Susan Ashley M.D

Heerspink 1 , 2 Maria Soler 3 Jelle M

Medications affecting cortisol or growth hormone directly may require timing adjustment

Small choices at the reconstitution stage compound across an entire study

Similar content being viewed by others Log in or create a free account to read this content Gain free access to this article, as well as selected content from this journal and more on nature.com or References Sekar R, Singh K, Arokiaraj AW, Chow BK

Its best to talk with your healthcare provider first, as they can help you transition off safely and maintain your progress through lifestyle support